AZ licences NASH treatment from Ionis for $30m

BMS gains shareholder backing for Celgene merger

AstraZeneca is paying $30 million to license Ionis Pharmaceuticals’ NASH treatment, IONIS-AZ6-2.5-LRx (or AZD2693).

AZ will be responsible for further development and commercialization of IONIS-AZ6-2.5-LRx.

“This is the third drug to enter development under our strategic collaboration with AstraZeneca to discover drugs to treat cardiovascular, renal and metabolic diseases,” said Brett P. Monia, Chief Operating Officer, senior vice president of antisense drug discovery and translational medicine at Ionis Pharmaceuticals.

“AstraZeneca has played a strategic role in advancing this program forward by providing both preclinical and development expertise in NASH that has contributed to the rapid advance of this drug into development.

We look forward to AstraZeneca moving this program swiftly into clinical testing and ultimately to the market.”

As IONIS-AZ6-2.5-LRx advances in development, Ionis may also receive up to $300 million in additional development and regulatory milestone payments, as well as tiered royalties up to the low teens from sales of the drug.